Manulife (Manufacturers Life Insurance)
SPRO icon

Manulife (Manufacturers Life Insurance)’s Spero Therapeutics SPRO Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,620
Closed -$101K – 3127
2022
Q1 		$101K Sell
11,620
-2,436
-17% -$25K ﹤0.01% 2956
2021
Q4 		$225 Sell
14,056
-220
-2% -$3.49K ﹤0.01% 2828
2021
Q3 		$263K Sell
14,276
-1,665
-10% -$26.7K ﹤0.01% 2778
2021
Q2 		$223K Buy
15,941
+2,484
+18% +$34.7K ﹤0.01% 3026
2021
Q1 		$198K Buy
13,457
+91
+0.7% +$1.6K ﹤0.01% 2899
2020
Q4 		$259K Buy
+13,366
New +$208K ﹤0.01% 2605
2018
Q3 		– Sell
-664
Closed -$10K – 3778
2018
Q2 		$10K Sell
664
-62
-9% -$793 ﹤0.01% 3891
2018
Q1 		$10K Sell
726
-402
-36% -$4.88K ﹤0.01% 3928
2017
Q4 		$13K Buy
+1,128
New +$13.8K ﹤0.01% 3915

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s SPRO Position: Q2 2022 in Review

Manulife (Manufacturers Life Insurance) sold out of Spero Therapeutics (SPRO) in Q2 2022, closing a stake of 11,620 shares — an estimated $101K sold.

Manulife (Manufacturers Life Insurance) first reported a position in SPRO in Q4 2017 and held it in 9 quarters. The position peaked at $263K in Q3 2021. 79 funds tracked by Wall St. Rank hold SPRO as of Q2 2022.

  • Manulife (Manufacturers Life Insurance) reported no remaining Spero Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 11,620 Spero Therapeutics shares in Q2 2022, an estimated $101K.
  • Manulife (Manufacturers Life Insurance) first reported a position in Spero Therapeutics in Q4 2017 and held it in 9 quarters.
  • Manulife (Manufacturers Life Insurance)'s Spero Therapeutics position peaked at $263K in Q3 2021.
  • 79 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2022.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2022, filed 15 Aug 2022.